ClinicalTrials.gg
Not yet recruitingNCT06458907TRICAV-IIUpdated Nov 17, 2026

A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

An interventional study of TricValve System and Optimal medical therapy in Tricuspid Valve Disease, Heart Valve Diseases and Cardiovascular Diseases, sponsored by P+F Products + Features USA Inc.. Not yet recruiting at 34 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionTricuspid Valve InsufficiencyRegistry: Heart Valve DiseasesReclassifiedWhy we changed it
Registry
Heart Valve Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tricuspid Valve Insufficiency
Why
  1. The study's listed conditions name Tricuspid Valve Insufficiency, a narrower term within Heart Valve Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by P+F Products + Features USA Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
780
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Tricuspid Valve Insufficiency with a site in United States — 27 open to participants now, 36 under way, none of them phase 3. Tricuspid Valve Insufficiency · United States.

Planned enrollment
5th of 42
780 · median 63
Started
2026
with 9 others
No phase
39 of 60
18 open now
Primary completion
2028-11
later than 25 of 35 live
Registered
44th of 60
by date
Lead sponsor
2 of 60
P+F Products + Features USA Inc.

Among the 60 studies in Tricuspid Valve Insufficiency with a site in United States, this one is the 5th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2026, is one of 39 with no phase, reaches primary completion later than 25 of the 35 other live ones, and was the 44th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

27 of the 60 studies in Tricuspid Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Tricuspid Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

Pivotal trial to evaluate the safety and effectiveness of the P\&F TricValve® Transcatheter Bicaval Valve System.

Read the detailed description

The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TricValve System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with severe tricuspid regurgitation and unsuitable for approved transcatheter therapies. Subjects will be followed at discharge, 1 month, 30 days, 3 months, 6 months 12 months, and annually up to 5 years.

03

Conditions studied

  • Tricuspid Valve Disease
  • Heart Valve Diseases
  • Cardiovascular Diseases
  • Heart Failure
  • Tricuspid Valve Regurgitation
  • Tricuspid Valve Insufficiency
04

In context

Tricuspid Valve Insufficiency Reclassified

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

This study's planned enrollment of 780 is above the median of 60 across 129 interventional studies indexed under Tricuspid Valve Insufficiency.

Browse Tricuspid Valve Insufficiency studies →

Lead sponsor

P+F Products + Features USA Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Tricuspid Valve Insufficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Valve Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility Criteria for Randomized Cohort:

Inclusion Criteria:

  1. Age between 18 years and 85 years old, at the time of signing the .
  2. Severe tricuspid regurgitation (TR) and Caval Reflux (CR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab. TVARC criteria will be used for the definition of TR severity.
  3. Class II-III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
  4. Adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team at the time of TR assessment for eligibility (TTE). OMT includes stable oral diuretic medications.
  5. High risk for open surgery and is appropriate for transcatheter tricuspid therapies according to the local heart team.
  6. Patient is unsuitable for approved transcatheter therapies and is eligible for the TricValve procedure, based on review of screening/baseline data and imaging core lab measurements by Central Screening Committee.
  7. For females of , negative pregnancy test.
  8. Capable and willing to provide signed informed consent

Exclusion Criteria:

CONCOMITANT PROCEDURES

  1. Patient had a recent MI, stroke, or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.
  2. Patient requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction.

    CARDIOVASCULAR CONDITIONS

  3. ≤ 30% on echocardiography.
  4. Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.
  5. Severe right ventricular dysfunction.
  6. Cardiac amyloidosis.
  7. Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.
  8. Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to the TricValve procedure.
  9. Hemodynamically significant pericardial effusion.
  10. Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.
  11. Patient with heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure).
  12. Presence of significant congenital or acquired heart disease such as RV dysplasia, arrhythmogenic RV or other conditions that could interfere with the TricValve procedure.

    ALLERGIES / INTOLERANCE

  13. Any known allergy or to nitinol, bovine tissue, or contrast media that cannot be adequately treated with pre-medication.
  14. Unable to tolerate anticoagulation/antiplatelet therapy

    COMORBIDITIES

  15. Any known life-threatening condition with an estimated life span of less than 12 months.
  16. count \< 75,000/mm3
  17. Severity Class C (10-15 points).
  18. Severe renal insufficiency with estimated (eGFR) ≤ 30 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.
  19. Endocarditis or active/ongoing infection requiring antibiotics.
  20. Unable to walk at least 100 meters in a 6-minute walk test.
  21. Known bleeding or clotting disorders or patient refuses blood transfusion.
  22. Active gastrointestinal (GI) bleeding within 3 months of TricValve procedure.
  23. Prior : this study excludes participants at material risk of near-term cancer-related morbidity/mortality that could confound 12-month outcomes. This study allows the inclusion of fully treated, remote malignancies with documented No Evidence of Disease (NED)" criteria

    a. History of any malignancy within 5 years prior to randomization or any active malignancy, except: i. Adequately treated non-melanoma skin cancer (basal or squamous cell) with no evidence of disease, or ii. Carcinoma in situ (e.g., cervical, breast DCIS) treated with curative intent and no evidence of disease.

    b. Participants with a prior malignancy diagnosed >5 years before randomization are eligible if they meet all of the "No Evidence of Disease (NED)" criteria as specified below: i. No signs/symptoms of cancer on history and physical exam per standard of care; ii. No radiologic evidence of disease on surveillance imaging if such imaging is routinely indicated for that tumor type (not protocol-mandated); iii. Tumor markers (if applicable for that cancer) not suggestive of recurrence (e.g., stable/undetectable within site's lab reference and oncologist's judgment); iv. No active anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy, radiotherapy) and none planned; v. Treating oncologist's attestation (or primary physician if oncology follow-up is complete) that the participant is disease-free and appropriate for participation.

    GENERAL EXCLUSIONS

  24. Use or participation in other device or drug study in which the patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.
  25. Any other condition that would preclude the ability to meet study requirements in the opinion of the investigator.
  26. Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up
  27. Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.

Eligibility Criteria for Single Arm Cohort:

Inclusion Criteria:

  1. Age > 85 years.
  2. NYHA Class III-IV, on intravenous inotropes, IABP or LVAD.
  3. LVEF ≤ 30% on echocardiography.
  4. Severe RV dysfunction.
  5. Severe pulmonary hypertension (PH), defined as Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or mean Pulmonary Artery Pressure (mPAP >35) by right heart catheterization.
  6. Renal insufficiency: eGFR between 25 and 30 mL/min/ 1.73 m² or on chronic renal replacement therapy.
  7. Patient unable to walk a minimum distance of 100 mt during 6 minute walk test.
  8. Prior malignancy not meeting the requirements applied for the Randomized Cohort, specified in Exclusion Criterion #23.
  9. Comorbidities precluding inclusion in the Randomized Cohort (exclusion criteria #15 to #24).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
780 participants (estimated)

Study arms

  • Experimental
    TricValve System + Optimal medical therapy (OMT)

    Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation.

    Device: TricValve System · Drug: Optimal medical therapy

  • Active comparator
    Optimal medical therapy (OMT) Alone

    OMT alone in patients with caval reflux and tricuspid regurgitation

    Drug: Optimal medical therapy

  • Experimental
    TricValve Single Arm Registry

    Single-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization

    Device: TricValve System · Drug: Optimal medical therapy

Interventions

  • DeviceTricValve System

    • Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

    Also known as: Heterotopic caval valve implantation (CAVI)

  • DrugOptimal medical therapy

    Optimal medical therapy

    Also known as: OMT

07

What researchers measure

Primary outcomes

  1. Randomized Cohort: Caval Reflux (CR) grade reduction

    Reduction in Caval Reflux (CR) assessed by the echocardiography core laboratory. The CR will be assessed using the 3-grade scale: Grade 1 (no reflux, reflux extending for less than 1 cm below the diaphragm), Grade 2 ( reflux extending for less than 3 cm), Grade 3 (reflux of 3 cm or more). Lower grades of CR are better.

    Time frame: 6 months

  2. Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement

    Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

    Time frame: 6 months

  3. Randomized Cohort: Rate of Major Adverse Events (MAE)

    Rate of Major Adverse Events (MAE) in experimental arm (TricValve + OMT)

    Time frame: 30 days

  4. Randomized Cohort: Hierarchical composite endpoint: all-cause mortality, RVAD implantation or heart transplant, tricuspid valve surgery or percutaneous tricuspid intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improv

    Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

    Time frame: 1 year

  5. Registry Cohort: Rate of Major Adverse Events (MAE)

    Rate of Major Adverse Events (MAE) in single arm registry

    Time frame: 30 days

Secondary outcomes

  1. Randomized Cohort: Percentage of Device- and/or Procedure-related MAEs

    Rate of Major Adverse Events

    Time frame: 1 year

  2. Randomized Cohort: All-Cause mortality and Cardiovascular Mortality

    Number of deaths from any cause as well as cardiovascular events

    Time frame: 6 months and 1 year

  3. Randomized Cohort: Heart Failure Hospitalizations (HFH)

    Number of Heart Failure Hospitalizations and worsening HF events without hospitilization

    Time frame: 6 months and 1 year

  4. Randomized Cohort: RVAD Implantation or Heart Transplant

    Number of patients requiring RVAD Implantation or Heart Transplant

    Time frame: 6 months and 1 year

  5. Randomized Cohort: Atrial Fibrillation

    New onset of atrial fibrillation

    Time frame: 1 year

  6. Randomized Cohort: Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) .

    Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

    Time frame: 6 months and 1 year

  7. Randomized Cohort: Changes in symptom status New York Heart Association (NYHA class)

    Reduction of at least 1 class from baseline. The NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

    Time frame: 6 months and 1 year

  8. Randomized Cohort: Changes in functional capacity (6-minute walk test, 6MWT).

    Improvement of 6-minute walk distance of at least 30 meters from baseline.

    Time frame: 6 months and 1 year

  9. Registry Cohort: Heart Failure Hospitalization

    Comparison of the 12-month post-procedure HFH rate with the 12-month pre-procedure rate

    Time frame: 1 year

  10. Registry Cohort: Changes in Quality of life (by Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score).

    Change from baseline to 12 months. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

    Time frame: 1 year

  11. Roll-In Cohort: Percentage of Device- and/or Procedure-related MAEs

    Rate of Major Adverse Events

    Time frame: 1 year

  12. Roll-In Cohort: All-Cause mortality and Cardiovascular Mortality

    Number of deaths from any cause as well as cardiovascular events

    Time frame: 6 months and 1 year

  13. Roll-In Cohort: Heart Failure Hospitalizations (HFH)

    Number of Heart Failure Hospitalizations and worsening HF events without hospitalization

    Time frame: 6 months and 1 year

  14. Roll-In Cohort: RVAD Implantation or Heart Transplant

    Number of patients requiring RVAD Implantation or Heart Transplant

    Time frame: 6 months and 1 year

  15. Roll-In Cohort: Atrial Fibrillation

    New onset of atrial fibrillation

    Time frame: 1 year

  16. Roll-In Cohort: Quality of life as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).

    Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life

    Time frame: 6 months and 1 year

  17. Roll-In Cohort: New York Heart Association (NYHA) functional class

    Reduction of at least 1 class from baseline. NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

    Time frame: 6 months and 1 year

  18. Roll-In Cohort: 6-minute walk test (6MWT).

    Improvement of 6-minute walk distance of at least 30 meters from baseline.

    Time frame: 6 months and 1 year

08

Study locations

34 sites
09

References and documents

Publications

  • Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A, Cruz-Gonzalez I, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Blasco-Turrion S, Sanchez-Luna JP, Revilla-Orodoea A, Redondo A, Zamorano JL, Puri R, Iniguez-Romo A, San Roman A. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention. 2023 Aug 7;19(5):e450-e452. doi: 10.4244/EIJ-D-23-00077. No abstract available. PubMed 37083622 ↗
  • Blasco-Turrion S, Briedis K, Estevez-Loureiro R, Sanchez-Recalde A, Cruz-Gonzalez I, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Sanchez-Luna JP, Gonzalez-Gutierrez JC, Revilla-Orodoea A, Zamorano JL, Gomez-Salvador I, Puri R, San Roman JA, Amat-Santos IJ. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes. JACC Cardiovasc Interv. 2024 Jan 8;17(1):60-72. doi: 10.1016/j.jcin.2023.10.043. Epub 2023 Dec 6. PubMed 38069986 ↗

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 24 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2024
First posted
Jun 14, 2024
StartEst.
Nov 2026was Aug 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2032
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Nov 2026
moved 2 times, Oct 9, 2026 – Nov 17, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • Cardiovascular Institute of the South · Houma, United StatesContact t•••@cardio.com · •••5040→j•••@cardio.com · •••5037
  • Kaiser Permanente · San Jose, United StatesContact added c•••@kp.org · •••4224Contact added (no phone or email listed)
  • HCA Florida Largo Hospital · Largo, United StatesContact added h•••@hcahealthcare.com · •••3721
  • Oregon Health · Portland, United StatesContact added r•••@ohsu.edu · •••1147Contact added (no phone or email listed)
  • Intermountain Heart Institute - Intermountain Medical Center · Murray, United StatesContact added m•••@imail.org · •••0978Contact added (no phone or email listed)
across 2 updates, Oct 9, 2026 – Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Start date Oct 2026→Nov 2026
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Kaiser Permanente · San Jose, United StatesContact added c•••@kp.org · •••4224Contact added (no phone or email listed)
    • HCA Florida Largo Hospital · Largo, United StatesContact added h•••@hcahealthcare.com · •••3721
    • Cardiovascular Institute of the South · Houma, United StatesContact t•••@cardio.com · •••5040→j•••@cardio.com · •••5037
    • Oregon Health · Portland, United StatesContact added r•••@ohsu.edu · •••1147Contact added (no phone or email listed)
    • Intermountain Heart Institute - Intermountain Medical Center · Murray, United StatesContact added m•••@imail.org · •••0978Contact added (no phone or email listed)
    + 1 other change: verification date
  2. Oct 9, 2026
    Start date Aug 2026→Oct 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cardiovascular Institute of the South · Houma, United StatesContact added t•••@cardio.com · •••5040Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06458907
Lead sponsor
P+F Products + Features USA Inc.
Collaborators
Meditrial USA Inc.
Responsible party
Sponsor
First posted
Jun 14, 2024
Start date
Nov 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2032 (estimated)
Last update
Nov 17, 2026

Study contacts

Thuy Olender
Contact
tolender@productsandfeatures.com
+1 408-839-3809

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion